Primary and secondary prevention of heart failure with statins

Authors: Udell, Jacob A; Ray, Joel G

Source: Expert Review of Cardiovascular Therapy, Volume 4, Number 6, November 2006 , pp. 917-926(10)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Statins are effective in the prevention of coronary heart disease (CHD), a leading cause of heart failure (HF). Secondary analyses from 11 randomized clinical trials of patients with high-risk acute or stable coronary heart disease, but without HF, suggest that statins may prevent new-onset HF or HF-related hospitalization. In persons with established HF, several cohort studies found an approximate 35% relative risk reduction in all-cause mortality. While ongoing randomized clinical trials will help to determine the efficacy of statins in persons with established HF, it is reasonable to consider this class of medications in patients with a history of cardiovascular disease, dyslipidemia or diabetes mellitus, and who have either developed, or who remain at risk of, HF.

Keywords: acute myocardial infarction; arrhythmia; atorvastatin; death; heart failure; mortality; pravastatin; simvastatin; statin; stroke

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14779072.4.6.917

Publication date: 2006-11-01

More about this publication?

Expert Review of Cardiovascular Therapy provides expert commentary on the clinical applications of the new medicines, therapeutic agents and diagnostics in cardiovascular disease. Coverage inculdes drug therapy, heart disease, vascular disorders, hypertension, cholesterol in cardiovascular disease, heart disease, stroke, heart failure and cardiovascular surgery.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites